|Bid||56.00 x 800|
|Ask||56.43 x 900|
|Day's Range||56.11 - 57.69|
|52 Week Range||12.51 - 73.72|
|Beta (5Y Monthly)||1.95|
|PE Ratio (TTM)||81.77|
|Earnings Date||Feb. 04, 2020 - Feb. 09, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||68.14|
Dosed the first patient in AROAAT2002, an open-label Phase 2 clinical study of ARO-AAT
Arrowhead files CTA for Phase 1 clinical trial of ARO-HSD, the company’s RNAi therapeutic for alcohol and nonalcohol related liver diseases like NASH
Arrowhead Pharmaceuticals appointed veteran pharmaceutical industry executive Marianne De Backer, Ph.D., as an independent director of the company
Arrowhead Pharmaceuticals Files IND for Phase 1b Study of ARO-HIF2 for Treatment of Clear Cell Renal Cell Carcinoma
Arrowhead Pharmaceuticals Closes Underwritten Public Offering with Gross Proceeds of $266.8 Million
Arrowhead Pharmaceuticals Inc. (ARWR) today announced the pricing of an underwritten public offering of 4,000,000 shares of its common stock, offered at a price of $58.00 per share, before underwriting discounts. The offering is expected to close on or about December 6, 2019, subject to customary closing conditions. In addition, Arrowhead has granted the underwriters of the offering a 30-day option to purchase up to an additional 600,000 shares of common stock at the public offering price, less the underwriting discount.
Arrowhead Pharmaceuticals Inc. (ARWR) today announced its intention to offer and sell 4,000,000 shares of its common stock in an underwritten offering pursuant to its existing automatic shelf registration statement. All of the shares in the proposed offering are to be sold by Arrowhead. Arrowhead intends to grant the underwriters a 30-day option to purchase up to an additional 600,000 shares of its common stock.
Shareholders will be ecstatic, with their stake up 34% over the past week following Arrowhead Pharmaceuticals, Inc.'s...
Arrowhead Pharmaceuticals Inc. today announced that it is scheduled to participate in the following upcoming events:
Arrowhead Pharmaceuticals, Inc. (ARWR) today announced that Bruce Given, M.D., Arrowhead’s chief operating officer and head of R&D, plans to retire on May 1, 2020, after a more than 30 year career in biotechnology and pharmaceutical research, development, and sales and marketing. Arrowhead also announced the hiring of Javier San Martin, M.D., in the role of chief medical officer, and Curt Bradshaw, Ph.D., in the role of chief scientific officer, both effective on Monday, November 18, 2019. During the next six months, Dr. Given will work closely with Dr. San Martin and Dr. Bradshaw to ensure a smooth transition and will also be retained in an advisory capacity for a period of at least one year following his retirement.
Arrowhead Pharmaceuticals Inc. (ARWR) today announced that it will host a webcast and conference call on November 25, 2019, at 4:30 p.m. EST to discuss its financial results for the fiscal year ended September 30, 2019. For analysts that wish to participate in the conference call, please dial 855-215-6159 or 315-625-6887 and provide Conference ID 7768049. To access the audio replay, dial 855-859-2056 or 404-537-3406 and provide Conference ID 7768049.
Arrowhead Pharmaceuticals Inc. today announced Phase 2 clinical data on a double combination of JNJ-3989 and a nucleos ide analog , and the first clinical data on a triple combination of JNJ-3989, JNJ-6379, and an NA, with collaborator Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson.
Arrowhead Pharmaceuticals Inc. (ARWR) today presented preclinical data at the 2019 North American Cystic Fibrosis Conference (NACFC) on ARO-ENaC, an inhaled RNAi therapeutic being developed as a potential treatment for cystic fibrosis (CF), which is a rare disease caused by genetic mutations that lead to mucus buildup in the lungs and pancreas. Arrowhead is currently conducting IND/CTA-enabling studies to support regulatory filings in the first half of 2020 for first-in-human studies. Bruce Given, M.D., chief operating officer and head of R&D at Arrowhead, said: “We view the epithelial sodium channel, ENaC, as an exciting target in the treatment of CF and one that is well suited to an RNAi-based intervention.